



- (51) **International Patent Classification:**
C07D 277/00 (2006.01) *A61K 38/06* (2006.01)
- (21) **International Application Number:**
PCT/US2013/066679
- (22) **International Filing Date:**
24 October 2013 (24.10.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/717,975 24 October 2012 (24.10.2012) US
61/721,244 1 November 2012 (01.11.2012) US
61/793,087 15 March 2013 (15.03.2013) US
- (71) **Applicant:** **ONYX THERAPEUTICS, INC.** [US/US];
249 E. Grand Avenue, South San Francisco, California
94080 (US).
- (72) **Inventors:** **JUMAA, Mouhannad**; 363 Catamaran Street,
Foster City, California 94404 (US). **MUCHAMUEL,**
Tony; 140 Dorrance Road, Boulder Creek, California
95006 (US). **BEJUGAM, Naveen**; 3585 Agate Drive, Apt
204, Santa Clara, California 95051 (US). **WONG,**
Hansen; 1548 Parkwood Drive, San Mateo, California
94403 (US). **KIRK, Christopher J.**; 391 Carl St., San
Francisco, California 94117 (US). **MANEK, Rahul**
Vishram; 101 Brigantine Road, Vallejo, California 94591
(US). **SHARMA, Sanjeev**; 13068 Seagrove Street, San
Diego, California 92130 (US).
- (74) **Agents:** **DOLA, Kristen, A.** et al.; Marshall, Gerstein &
Borun LLP, 233 S. Wacker Drive, Chicago, IL 60606-6357
(US).
- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.
- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) **Title:** MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB

(57) **Abstract:** This disclosure features modified release pharmaceutical formulations (e.g., extended release pharmaceutical formulations; e.g., solid dosage forms, e.g., tablets) that are useful for the oral administration of oprozomib, or a pharmaceutically acceptable salt thereof, to a human or animal subject as well as methods of making and using the formulations.

